| Revenue growth | 32% YoY growth in FY26. |
|---|---|
| Margins | FY26 EBITDA margin improved to 18% from 9% in FY25. |
| Demand visibility | Recurring demand for SDA and environment-friendly catalysts. |
Growth
FY26 Revenue grew 32%, EBITDA surged 172%, and PAT increased 636% YoY to ₹421 Mn.
Outlook
Ongoing expansion in SDA and PASC segments; R&D focused on continuous flow chemistry and electrolysis.
Risks
Global geopolitical shifts, trust deficits between major economies, and increasing cost of labor.
Earnings Call filed with BSE, NSE: TATVA. Summary written with AI assistance from the document.
Tatva Chintan Pharma Chem Ltd: key numbers
- Share price
- ₹1,999.80
- Market cap
- ₹4,678 Cr
- Revenue (annual)
- ₹505.9 Cr
- Net profit (annual)
- ₹42.05 Cr
- P/E (TTM)
- 91.0×Sector 37.2×
- Promoter holding
- 72.02%+0.00% QoQ
- FII holding
- 3.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tatva Chintan Pharma Chem Ltd
All →Tatva Chintan Pharma Chem Annual General Meeting
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
Tatva Chintan Pharma Chem Credit Rating
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.
Tatva Chintan Pharma Chem Business Update
Tatva Chintan Pharma Chem Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report highlights its specialty chemicals operations and ESG metrics.
Tatva Chintan Pharma Chem Annual Report
Tatva Chintan Pharma Chem Limited has submitted its Annual Report for the financial year 2025-26. The company's 30th Annual General Meeting is scheduled for September 25, 2026.
Tatva Chintan Pharma Chem Annual General Meeting
Tatva Chintan Pharma Chem Limited has scheduled its 30th Annual General Meeting for September 25, 2026. Key agenda items include dividend declaration and director re-appointments.
Tatva Chintan Pharma Chem Annual General Meeting
Tatva Chintan Pharma Chem Limited scheduled its 30th AGM for September 25, 2026. Key agenda items include dividend declaration and increasing borrowing limits to ₹1,000 Crore.
- Value
- ₹1,000 Cr